Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18892213 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA4KDM4EIP6K1MAP4K4 | |
| SCHEMBL22403202 | 0.88 | ACVR1 (0.37) | CHRNB2CHRNA4MAPTMETALDH1A1 | |
| SCHEMBL18891808 | 0.87 | ACVR1 (0.37) | KDM4EMAPTMETHSD17B10MEN1 | |
| SCHEMBL21557651 | 0.87 | MAPK1 (0.32) | CHRNB2CHRNA4HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL21557618 | 0.82 | KDM4E (0.35) | CHRNB2CHRNA4KDM4EIP6K1MAP4K4 | |
| SCHEMBL18891806 | 0.82 | PIM3 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL18892242 | 0.82 | MET (0.40) | KDM4EMAPTMETHSD17B10MEN1 | |
| SCHEMBL18892219 | 0.81 | TP53 (0.36) | CHRNB2CHRNA4KDM4EIP6K1MAP4K4 | |
| SCHEMBL25970628 | 0.81 | BRD4 (0.44) | CHRNB2CHRNA4KDM4EIP6K1MAP4K4 | |
| SCHEMBL21557955 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2021-07-22 | — | — | US | disclosed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | disclosed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | disclosed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | disclosed |
| EP-3170822-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2017-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | CHRNB2 2890/4885CHRNA4 4004/4885KDM4E 3007/4885 |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | CHRNB2 2080/4885CHRNA4 3219/4885KDM4E 1475/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | CHRNB2 2890/4885CHRNA4 4004/4885KDM4E 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.